RecruitingNot Applicable

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

Germany40 participantsStarted 2024-05-05

Plain-language summary

The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up. * Patient has provided informed consent prior to enrollment. Exclusion Criteria: * No exclusion criteria

What they're measuring

Adverse Events

Timeframe: through study completion, up to 14 years

Trial details

NCT IDNCT06508775

SponsorMiltenyi Biomedicine GmbH

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2040-12-31

Contact for this trial

Clinical Trial Manager

+4922048306820 clinicaltrials.gov@miltenyi.com

View on ClinicalTrials.gov More Melanoma Stage III trials